Aggregator

Inconclusive evidence suggests zinc may slightly shorten common cold

1 year 7 months ago

A new Cochrane review has found that taking zinc may help to reduce the duration of common cold symptoms by about two days, but the evidence is not conclusive and potential benefits must be balanced against side-effects. 

Since the 1980s, zinc products have been marketed as treatments for the common cold and are particularly popular in the USA. Zinc is an essential mineral naturally found in many foods and plays a role in immune function. Most people in high-income countries get enough zinc through their diets, although aging and some chronic diseases may lead to deficiency. 

The theory behind zinc-based lozenges, sprays and syrups is that the zinc may interfere with viral replication when it comes into contact with viral particles in the nose, mouth and throat. Zinc has been shown to interfere with viral replication in petri dishes and mice, although this alone doesn't tell us whether something will work in real people. 

To test if zinc is useful in preventing or treating a cold, a team of researchers looked at 19 human trials examining zinc as a treatment and 15 as a preventative measure. They identified a lot of variation between the studies in how zinc was administered, how much was given, how they defined a ‘cold’ and what they measured. 

Eight studies with 972 participants investigated zinc as a treatment to reduce cold duration. Combining the results of these studies yielded low-certainty evidence that it may help to reduce duration by around two days, down from an average week-long duration in the groups who received placebo.  

The review found no strong evidence to conclude that zinc treatment impacts the severity of cold symptoms. The prevention studies showed no clear evidence of benefit from taking zinc before the onset of a cold; those taking zinc preventatively had similar outcomes to those who didn’t. 

Common side-effects of zinc reported in the trials included bowel problems, nausea and unpleasant taste. There was no clear evidence of more serious side-effects directly resultant from zinc. 

“People considering zinc to treat a cold should be aware of the limited evidence base and possible side-effects,” says Assistant Professor Daryl Nault of Maryland University of Integrative Health, first author of the review. “Ultimately, it’s up to the individual to decide whether the risk of potential unpleasant side-effects is worth the benefit of potentially shortening their illness by a few days. The best advice remains to consult your physician if you’re feeling unwell and inform them if you use any supplements. While there have been many trials investigating zinc, the approaches vary, so it is difficult to draw conclusions with certainty.” 

The trials included in the review varied in many ways including the type of zinc, the dose of zinc given, whether it was given as a lozenge or nasal spray, and how the outcomes were reported and measured. Some trials measured for a fixed time window and asked participants if they still had a cold at the end. Others measured the time between symptoms starting and resolving, although this was defined slightly differently by each study. Few studies monitored the status of individual symptoms, such as sore throat, cough or fever, so there was insufficient evidence to draw any reliable conclusions about specific symptoms. 

“The evidence on zinc is far from settled: we need more research before we can be confident in its effects,” says Assistant Professor Susan Wieland of the University of Maryland School of Medicine, senior author of the review. “Future studies should adopt standardized methods for administering and reporting treatments and defining and reporting outcomes. Additional studies focusing on the most promising types and doses of zinc products and using appropriate statistical methods to assess outcomes that are important to patients will enable us to understand whether zinc may have a place in treatment of the common cold.” 

Thursday, May 9, 2024
Muriah Umoquit

Cochrane seeks Systems Administrator (Full Time, remote – flexible)

1 year 7 months ago

Specifications: Permanent – Full Time (1.0 FTE.)
Salary:   circa £35,000 per Annum
Location: (Remote – Flexible) Ideally based in the UK, Germany or Denmark. Candidates anywhere from the world will be considered; however, Cochrane’s Central Executive Team is only able to offer consultancy contracts outside these countries for 1-Year.
Closing date: 21 April 2024

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into four directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.

To help maintain and evolve Cochrane’s cloud hosting and application deployment infrastructure, ensure applications’ dependencies are kept current (both independently and in collaboration with development teams), and promote operational awareness across the infrastructure. This role works across development and operations (DevOps).

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect:

  • An opportunity to truly impact health globally.
  • A flexible work environment
  • A comprehensive onboarding experiences.
  • An environment where people feel welcome, heard, and included, regardless of their differences.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations, and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

  • For further information on the role and how to apply
  • The deadline to receive your application is 21 April 2024.
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
  • Read our Recruitment Privacy Statement
Monday, April 15, 2024 Category: Jobs
Lydia Parsonson

Building stronger evidence ecosystems together: Cochrane, JBI, and Campbell's call to action

1 year 7 months ago

We are thrilled to announce the publication of a new editorial titled "Unlocking the Power of Global Collaboration: Building a Stronger Evidence Ecosystem Together," authored by Prof Zoe Jordan of JBI, Dr Vivian Welch of The Campbell Collaboration, and Dr Karla Soares-Weiser of Cochrane. This editorial is now available simultaneously in JBI Evidence Synthesis, Campbell Systematic Reviews, and the Cochrane Database of Systematic Reviews. It underscores the urgent need for collaborative efforts to harness the potential of evidence synthesis on a global scale. This collaborative endeavour reflects the shared commitment of the three organisations to foster cooperation, aiming to enhance both health outcomes and policy efficacy worldwide.

The editorial highlights the pivotal role of collaboration in addressing contemporary global challenges, emphasizing the collective commitment of JBI, The Campbell Collaboration, and Cochrane to foster cooperation for enhanced health outcomes and policy efficacy worldwide. Dr. Karla Soares-Weiser said: "This co-publication marks a significant milestone for all three of our organizations and reaffirms our dedication to collaboration. Our respective communities are profoundly collaborative and communicative within their domains, and we'd now like to catalyze further collaboration between and across them. We're particularly excited about the upcoming Global Evidence Summit, where leaders in evidence synthesis and evidence-based practice, including Cochrane, JBI, Guidelines International Network (GIN), and The Campbell Collaboration, will convene to share best practice and promote cross-disciplinary working."

Scheduled for September 2024, the Global Evidence Summit represents a unique opportunity for professionals across various sectors to engage in discussions about evidence production, summarization, and dissemination, informing policy and practice. Dr. Soares-Weiser emphasized the importance of this event: "The GES serves as a platform for knowledge exchange and collaboration, crucial for addressing global challenges in health, education, social justice, and the environment." As the editorial advocates for a shift towards enhanced collaboration, the Global Evidence Summit sets the stage for meaningful dialogue and action.


Jordan Z, Welch V, Soares-Weiser K. Unlocking the power of global collaboration: building a stronger evidence ecosystem together. Cochrane Database of Systematic Reviews 2024, Issue 4. Art. No.: ED000166. DOI: 10.1002/14651858.ED000166.

Tuesday, April 16, 2024
Muriah Umoquit

Active case finding for TB must be paired with effective follow-up care, Cochrane review finds

1 year 7 months ago

Door-to-door tuberculosis (TB) screening and contact tracing can improve diagnosis rates, but must be paired with effective follow-up care to be successful, a new Cochrane review has found.

Active case finding (ACF) seeks to improve diagnosis rates in people living in communities who may not otherwise present to health facilities, helping them access treatment and reduce onward transmission.

Despite being a key strategy of most TB strategies globally, there is often little consideration of how these programmes are experienced by communities. This is essential in designing appropriate and effective services.

Published ahead of World TB Day (24 March), a new review published by Cochrane Infectious Diseases, based at Liverpool School of Tropical Medicine, looked at studies of community experiences towards ACF programmes for TB in any endemic low- or middle-income country. This was a qualitative evidence synthesis that looked at the evidence from 45 studies. 

Senior author and Cochrane Infectious Diseases Editor, Professor Sandy Oliver,  said, “The power of qualitative syntheses like these is in their ability to capture rich information from various contexts to develop a deep understanding of how policies play out in the real world – how services deliver them, how communities receive them or avoid them, what might make them work a little better, and why”.

The review authors found that ACF improves access to diagnosis for many, but does little for those in financial need to continue care. People may also experience stigma in relation to screening.

It was also shown that ACF can create expectations for follow-up care that health systems may not be able to meet, as well as health workers finding it difficult to implement.

This Cochrane Review will help to better understand policy in action and the perceived benefit relative to the harm of ACF.

Lead author Melissa Taylor said: “Active case finding brings diagnosis to many of those who may otherwise not have received it. However, our review demonstrates it is essential that active case finding is linked to well-resourced follow up services and wider health system strengthening.”

Taylor M, Medley N, van Wyk SS, Oliver S. Community views on active case finding for tuberculosis in low‐ and middle‐income countries: a qualitative evidence synthesis. Cochrane Database of Systematic Reviews 2024, Issue 3. Art. No.: CD014756. DOI: 10.1002/14651858.CD014756.pub2

Thursday, March 21, 2024
Muriah Umoquit

細気管支炎を起こした乳幼児に対する高流量鼻カニューレ(チューブ)酸素療法

1 year 7 months ago
細気管支炎を起こした乳幼児に対する高流量鼻カニューレ(チューブ)酸素療法 細気管支炎とは? 細気管支炎は、(細い)下気道におこる、乳幼児(月齢24か月未満)によく見られる病気である。通常、ウィルス感染が原因となり、咳、速い呼吸、喘鳴などの呼吸障害を引き起こすが、哺乳不良となる可能性もある。これは乳幼児が入院する主な原因の一つである。細気管支炎の治療は対症療法である。つまり、入院が必要な場合は、感染症が治るまで、患児の呼吸を補助することになる。呼吸を助ける方法として、次第に多く採用されるようになっているのは、空気と酸素を混合し、加温、加湿したものを、鼻カニューレ(酸素供給用チューブ)を通じて、従来の(低流量)加湿しない酸素供給の最大流量である毎分2リットルより高い流量で供給する方法である。これは高流量鼻カニューレ療法として知られ、これによって空気と酸素の混合ガスを高流量で快適に供給し、換気を改善しうる。他方、持続的気道陽圧法(CPAP)も細気管支炎の治療に次第に多く使われるようになっている。この療法では、空気と酸素の混合ガスを事前に設定された気圧で供給することによって、気道を開いた状態に保ち、呼気時(息を吐くとき)に虚脱が起きないようにする。 調べたかったこと 高流量酸素療法は、侵襲的な呼吸補助(挿管(人工呼吸)など)の必要性の低減につながりうるほか、上気道の乾燥を防ぐなど、他の治...

心理療法は、長期療養を受ける高齢者のうつ病を軽減するのに有効か?

1 year 7 months ago
心理療法は、長期療養を受ける高齢者のうつ病を軽減するのに有効か? 要点 - 長期療養(LTC)施設(例えば、介護施設や老人ホーム、介護付き有料老人ホームなど)に居住する高齢者では、心理療法(トーキング・セラピーとして知られることもある)は心理療法でないケアよりもうつ病の症状をよく治療する可能性がある。 - 心理療法はまた、生活の質(QOL)や心理的ウェルビーイング(個人の情緒的健康と全体的機能)を短期的に向上させるためには、心理療法でないケアよりも優れているかもしれない。 - 十分なエビデンスがないため、心理療法の広範な利益や長期的な効果は不明である。 調べたかったこと 心理療法がLTC環境におけるうつ病の管理に有益かどうかを調べたかった。 重要である理由 うつ病はLTCで暮らす高齢者によく見られる。このような人々は、うつ病を治療するために薬を処方されることが多い。心理療法が有効な選択肢になるかもしれない。 高齢者のうつ病の治療には、どのような心理療法があるか? LTC生活者のうつ病を治療する心理療法には、行動療法、認知行動療法、回想療法などがある。 実施したこと LTC施設で生活するうつ病の高齢者に対する心理療法を、代わりのケアと比較した研究を検索した。治療終了後、短期(3か月まで)、中期(3か月から6か月)、長期(6か月以上)の追跡調査における結果(評価項目)を検討した。 研...

メトホルミンは成人の2型糖尿病に有効な治療薬か?

1 year 7 months ago
メトホルミンは成人の2型糖尿病に有効な治療薬か? 背景 2型糖尿病は、血糖値(血液の糖分濃度)が高くなっている状態の病気である。血糖値は、膵臓で作られるホルモンであるインスリンによってコントロールされている。インスリンは、肝臓、筋肉、脂肪細胞に、血液から糖分を取り除き、蓄えるように指示をする。膵臓で十分なインスリンが作られない、または体がインスリンに反応しなかったりする場合、血液中に糖分が多く残ってしまう。2型糖尿病の治療薬は数多くある。これらの治療薬は、血液中の糖の量を減らし(血糖値を下げ)、糖尿病の長期合併症を軽減することを目的としている。2型糖尿病の人に通常最初に処方される薬は、メトホルミンである。メトホルミンは、肝臓が血液中に放出する糖分の量を減らす作用がある(血糖値が上がるのを防ぐ)。また、インスリンに対する体の反応を改善する。 メトホルミンが2型糖尿病の治療薬として有効かどうか、またメトホルミンが望ましくない(有害な)効果を引き起こすかどうかを調べたかった。また、他の糖尿病薬や、食事療法、運動療法、あるいはその両方との効果も比較したかった。特に注目したアウトカム(結果、評価項目)は、死亡、重篤な望ましくないイベント、健康関連の生活の質 (QOL)、心血管系の原因による死亡、および糖尿病の非致死的な合併症(例えば心臓発作、脳卒中、腎不全など)であった。 何を調べようとし...

在宅ホスピタル実施に関する複数の認識

1 year 7 months ago
在宅ホスピタル実施に関する複数の認識 要点 - 在宅ホスピタルサービスを開発する際には、医療専門家が患者を紹介するためのわかりやすいプロセスを設定することが重要である。これには、サービスがどのような人に適しているかを定めた明確なガイドラインを作成することも含まれる。 - 在宅ホスピタルサービスには、スタッフ、患者、介護者間の明確で一貫したコミュニケーションとともに、安全で効果的な患者中心のケアを在宅で提供するスキルを持った訓練された労働力が必要である。 - 在宅ホスピタルサービスを新たに導入する際、あるいは既存のサービスを運営する際に、医療専門家や管理者が使用するための質問をいくつか提案する。この質問は、在宅ホスピタルサービスの計画と実施に役立て、スタッフ、患者、介護者の満足度と結果(評価項目)を向上させることを目的としている。 在宅ホスピタルとは? 在宅ホスピタルでは、病院に入院しなければならない人々を対象に、病院レベルのケアを自宅で提供する。在宅ホスピタルの1つのタイプは、入院を避けることである。これは入院回避在宅ホスピタルと呼ばれる。これらのサービスは、肺疾患の再燃など、通常であれば病院のベッドでの治療が必要な人を対象とし、入院に代わるものである。その代わり、医師は、自宅(または、入所施設を含む、普段生活している場所)で病気の治療を受けるのに適していると評価した患者を、期間...

Purse-string skin closure for stoma reversal: evidence of practice-changing benefits

1 year 7 months ago

In this blog for colorectal surgeons and health professionals involved in stoma reversals, Dr Stina Öberg, Dr Siv Fonnes, and Professor Jacob Rosenberg from the Cochrane Colorectal Group discuss new practice-changing Cochrane evidence, showing that a simple change of suture technique likely results in a large reduction in surgical site infections in people undergoing stoma reversal.

Take-home points

  • The stoma closure site can be considered a clean-contaminated wound, and many patients develop a surgical site infection after having a temporary ileostomy or colostomy reversed.
  • Surgeons often use linear skin closure after stoma reversal. In theory, a clean-contaminated wound can benefit from drainage, which is achieved by using the purse-string skin closure technique.
  • A new Cochrane Review has demonstrated that the purse-string skin closure technique likely results in a large reduction in surgical site infections after stoma reversal compared with linear skin closure.
  • This simple and inexpensive change of practice may also improve patient satisfaction slightly. Even though the evidence is very uncertain, there seems to be no difference in incisional hernias.

Can surgeons improve their skin closure technique after stoma reversal? Yes - in a straightforward way! Researchers have found clinically important evidence in a new Cochrane review, showing that a simple change of suture technique likely results in a large reduction of surgical site infections in people undergoing stoma reversal. This blog presents the key results from this Cochrane review.

Skin closure after stoma reversal
Temporary stomas are created to protect distal bowel segments. At the time of stoma reversal, the last step is to close the skin. Due to the proximity to intestinal content, the stoma closure site should be considered a clean-contaminated wound. This could also explain why surgical site infections are common after stoma reversal, occurring in up to 40% of patients. When a wound is potentially contaminated, it will in theory benefit from free drainage.

Linear skin closure
Most surgeons use linear (transverse) skin closure despite the possible contamination of the wound at the stoma reversal site. Linear skin closure provides poor or no wound drainage and is theoretically a poor choice for a clean-contaminated wound. The stoma reversal wound is often close to a circular shape, and there is an alternative skin closure technique that at the same time provides drainage - the purse-string technique.

Purse-string skin closure
The purse-string skin closure technique can be used for circular or ellipse-formed wounds. The technique is performed by using intradermal sutures that are drawn together like an old-fashioned drawstring purse (see illustration at the top of the page), leaving a small opening in the centre. The theoretical advantage of using purse-string skin closure for a clean-contaminated wound is that it provides free drainage. This advantage could lower the risk of developing surgical site infections compared with linear skin closure. A lower surgical site infection risk could also result in a better cosmetic result, a higher patient satisfaction, and fewer incisional hernias.

What are the benefits of the purse-string skin closure?
In the Cochrane review comparing purse-string skin closure versus linear skin closure in people undergoing stoma reversal, surgical site infection was assessed in nine randomised controlled trials including almost 800 patients. The purse-string technique likely results in a large reduction in surgical site infections compared with linear skin closure. The anticipated risk within 30 days after linear closure was 243 surgical site infections per 1000 patients versus 52 (95% confidence interval 28 to 85) per 1000 patients after purse-string skin closure.

Purse-string closure may also have other advantages over linear closure. Patients who received the purse-string skin closure seemed to be slightly more satisfied six and twelve months after surgery: the anticipated effect in two randomised controlled trials was 885 satisfied or very satisfied patients per 1000 patients having linear skin closure versus 994 (95% confidence interval 894 to 1000) per 1000 patients having purse-string skin closure.

Finally, a reduced risk of surgical site infections could reduce the risk of incisional hernias. This outcome was reported by four randomised controlled trials with nearly 300 patients followed between three and twelve months, showing an anticipated risk of 55 incisional hernias per 1000 patients after linear skin closure versus 29 (95% confidence interval 4 to 177) per 1000 patients having purse-string skin closure. Even though the purse-string skin closure theoretically could lower the risk of incisional hernias, this was not shown, and there seems to be little to no difference in the risk of developing incisional hernias regardless of the skin closure technique used. However, the evidence is very uncertain, and further randomised controlled trials with longer follow-up might alter this result.

What are the benefits of linear skin closure?
The Cochrane review showed no advantage of using linear skin closure compared with purse-string skin closure in patients undergoing stoma reversal.

What are the risks of the purse-string skin closure?
The Cochrane review suggested that there was no evidence of an increased risk when patients received the purse-string technique compared with linear skin closure.

Pros and cons of purse-string versus linear skin closure
To summarise:

The benefits of using purse-string skin closure:

  • likely results in a large reduction in surgical site infections
  • may improve patient satisfaction slightly

The benefits of using linear skin closure:

  • none found

There seems to be no evidence of a difference between purse-string and linear skin closure regarding:

  • incisional hernia (but the evidence is very uncertain)
  • operative time (but the evidence is very uncertain)
  • length of hospital stay (but the certainty of evidence is unknown)
  • anastomotic leak (but the certainty of evidence is unknown)
  • intestinal obstruction (but the certainty of evidence is unknown)

Which skin closure technique is best to use after stoma reversal?
Purse-string skin closure both has the theory and the evidence to back up a lower risk of surgical site infections compared with linear skin closure, seemingly without any risks of complications. The result from this Cochrane review could make surgeons reconsider their skin closure method in patients undergoing stoma reversal. A change of practice from linear to purse-string skin closure is both straightforward and inexpensive.

Clinical reflections on the implications of the review
When asking Professor Jacob Rosenberg, the co-ordinating editor of the Cochrane Colorectal Group, about the clinical implications of this Cochrane Review, he stated that:

  • This review clearly shows that a simple change in skin closure technique can have a large impact on patient outcome after stoma reversal.
  • The purse-string skin closure technique for the stoma site is simple, effective, and seemingly without negative effects.
  • These results have the potential to change clinical practice around the world.
  • The recommendation to use the purse-string method for skin closure of stoma sites should be included in future clinical guidelines.

Read the full Cochrane Review and plain language summary in the Cochrane Library 

Listen to the lead author, Shahab Hajibandeh from Health Education and Improvement Wales, to tell us more about this review in three minutes

Hajibandeh S, Hajibandeh S, Maw A. Purse‐string skin closure versus linear skin closure in people undergoing stoma reversal. Cochrane Database of Systematic Reviews 2024, Issue 3. Art. No.: CD014763. DOI: 10.1002/14651858.CD014763.pub2. 

Image: The featured image at the top of the page was created by Malene Agnete Højland and Louise Rosengaard from the Cochrane Colorectal Group.

 

Tuesday, March 12, 2024
Muriah Umoquit

初回エピソードおよび最近発症した精神病における認知行動療法と標準治療の併用

1 year 7 months ago
初回エピソードおよび最近発症した精神病における認知行動療法と標準治療の併用 要点 認知行動療法(CBT)は統合失調症の症状を軽減し、統合失調症の初期段階の人々の機能を改善するのに有効である。 この介入に関連する潜在的な有害作用については、ほとんど情報がなかった。 背景 統合失調症は、その症状が患者の日常生活に大きな影響を及ぼすため、深刻な精神疾患である。この病気がある人は、自分の考え、思い込み、想念と現実を区別するのに苦労している。例えば、頭の中で声が聞こえることがあり、それが本当に誰かに話しかけられているように感じられる。病気の初期段階の治療は、慢性化を防ぐため、またはそのリスクを減らすために非常に重要である。この段階は通常「初回エピソード」と定義され、「最近発症した」という言葉は初回エピソードから3~5年の期間を表す言葉としても使われる。 心理学的介入である認知行動療法は、一般に統合失調症のある人の症状を抑えるのに有効である。 しかし、この介入が病気の初期段階の人々にも有効かどうかは、まだ明らかではない。 調べたかったこと 初回エピソードあるいは最近発症した統合失調症患者に対して、標準治療に認知行動療法を追加した場合の効果を調べたいと考えた。 行ったこと 標準治療(通常は薬物)に加えて認知行動療法を行い、標準治療単独または他の心理社会的介入と比較した研究を検索した。 研究結果...

がんワクチンは進行した非小細胞肺がんに効果があるのか

1 year 7 months ago
がんワクチンは進行した非小細胞肺がんに効果があるのか 要点 - このレビューで評価したワクチンによって進行非小細胞肺がん患者の余命や無増悪生存期間が延長することはないか、あってもごくわずかである。 - ワクチンによる好ましくない影響は頻繁に起こるものではない。 肺がんとは 肺がんは世界で最もよくあるがんのひとつである。非小細胞肺がん(NSCLC)は肺がんの中でも最も多いタイプで、肺がんの約87%を占める。非小細胞肺がんは進行した段階で診断されることが多く、死亡率が高く、余命も短い。 非小細胞肺がんの治療法は 非小細胞肺がんのほとんどが、まず化学療法で治療される。化学療法とは、急速に増殖するがん細胞を消滅させるための強力な化学物質からなる薬物療法である。NSCLC患者の生存率を向上させるための新しい治療法は、化学療法後の免疫療法による治療に焦点を当てている。がんワクチンは免疫療法の一種である。病気から私たちを守るためのワクチンとは異なり、がんワクチンはすでにがんに罹患している人のためのものである。治療用がんワクチンは、がん細胞を認識して破壊するように免疫系を刺激することを目的としている。 知りたかったこと ワクチンを接種することによって生存期間が延びるのか、病気の進行がない期間が延びるのか、また、ワクチンには好ましくない影響があるのかを知りたいと考えた。 実施したこと 進行NSCL...